{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:35:33Z","timestamp":1778780133172,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100012742","name":"Peregrine Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012742","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s11523-019-00663-3","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T05:02:38Z","timestamp":1566190958000},"page":"541-550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial"],"prefix":"10.1007","volume":"14","author":[{"given":"Ali A.","family":"Mokdad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad S.","family":"Beg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yull","family":"Arriaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan E.","family":"Dowell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit G.","family":"Singal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam C.","family":"Yopp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,19]]},"reference":[{"key":"663_CR1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamaoncol.2017.1747","volume":"3","author":"C Fitzmaurice","year":"2017","unstructured":"Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3:524\u201348.","journal-title":"JAMA Oncol."},{"key":"663_CR2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","volume":"56","author":"European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer","year":"2012","unstructured":"European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL\u2013EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908\u201343.","journal-title":"J Hepatol."},{"key":"663_CR3","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099\u2013109.","journal-title":"Cancer Res"},{"key":"663_CR4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00280-006-0393-4","volume":"59","author":"YS Chang","year":"2007","unstructured":"Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59:561\u201374.","journal-title":"Cancer Chemother Pharmacol"},{"key":"663_CR5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"663_CR6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"A-L Cheng","year":"2009","unstructured":"Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia\u2013Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25\u201334.","journal-title":"Lancet Oncol."},{"key":"663_CR7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11912-015-0494-5","volume":"18","author":"AA Mokdad","year":"2016","unstructured":"Mokdad AA, Singal AG, Yopp AC. Advances in local and systemic therapies for hepatocellular cancer. Curr Oncol Rep. 2016;18:9.","journal-title":"Curr Oncol Rep."},{"key":"663_CR8","first-page":"6132","volume":"62","author":"S Ran","year":"2002","unstructured":"Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 2002;62:6132\u201340.","journal-title":"Cancer Res"},{"key":"663_CR9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1194\/jlr.R200019-JLR200","volume":"44","author":"DL Daleke","year":"2003","unstructured":"Daleke DL. Regulation of transbilayer plasma membrane phospholipid asymmetry. J Lipid Res. 2003;44:233\u201342.","journal-title":"J Lipid Res"},{"key":"663_CR10","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1158\/1078-0432.CCR-07-1516","volume":"14","author":"M Jennewein","year":"2008","unstructured":"Jennewein M, Lewis MA, Zhao D, Tsyganov E, Slavine N, He J, et al. Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine. Clin Cancer Res. 2008;14:1377\u201385.","journal-title":"Clin Cancer Res"},{"key":"663_CR11","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1158\/0008-5472.CAN-05-0031","volume":"65","author":"X Huang","year":"2005","unstructured":"Huang X, Bennett M, Thorpe PE. A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice. Cancer Res. 2005;65:4408\u201316.","journal-title":"Cancer Res"},{"key":"663_CR12","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.bbamem.2011.07.026","volume":"1808","author":"S Riedl","year":"2011","unstructured":"Riedl S, Rinner B, Asslaber M, Schaider H, Walzer S, Novak A, et al. In search of a novel target\u2014Phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy. Biochim Biophys Acta BBA Biomembr. 2011;1808:2638\u201345.","journal-title":"Biochim Biophys Acta BBA Biomembr"},{"key":"663_CR13","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1002\/ijc.21684","volume":"118","author":"AW Beck","year":"2006","unstructured":"Beck AW, Luster TA, Miller AF, Holloway SE, Conner CR, Barnett CC, et al. Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. Int J Cancer. 2006;118:2639\u201343.","journal-title":"Int J Cancer"},{"key":"663_CR14","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1158\/1078-0432.CCR-07-0793","volume":"13","author":"J He","year":"2007","unstructured":"He J, Luster TA, Thorpe PE. Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids. Clin Cancer Res. 2007;13:5211\u20138.","journal-title":"Clin Cancer Res"},{"key":"663_CR15","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1158\/1078-0432.CCR-09-1499","volume":"15","author":"J He","year":"2009","unstructured":"He J, Yin Y, Luster TA, Watkins L, Thorpe PE. Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15:6871\u201380.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"key":"663_CR16","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1245\/s10434-016-5107-5","volume":"23","author":"X Cheng","year":"2016","unstructured":"Cheng X, Li L, Thorpe PE, Yopp AC, Brekken RA, Huang X. Antibody-mediated blockade of phosphatidylserine enhances the antitumor effect of sorafenib in hepatocellular carcinomas xenografts. Ann Surg Oncol. 2016;23:583\u201391.","journal-title":"Ann Surg Oncol"},{"key":"663_CR17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/37022","volume":"390","author":"RE Voll","year":"1997","unstructured":"Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature. 1997;390:350\u20131.","journal-title":"Nature"},{"key":"663_CR18","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1172\/JCI1112","volume":"101","author":"VA Fadok","year":"1998","unstructured":"Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine\/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest. 1998;101:890\u20138.","journal-title":"J Clin Invest"},{"key":"663_CR19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1078\/0171-2985-00217","volume":"207","author":"US Gaipl","year":"2003","unstructured":"Gaipl US, Beyer TD, Baumann I, Voll RE, Stach CM, Heyder P, et al. Exposure of anionic phospholipids serves as anti-inflammatory and immunosuppressive signal\u2013implications for antiphospholipid syndrome and systemic lupus erythematosus. Immunobiology. 2003;207:73\u201381.","journal-title":"Immunobiology"},{"issue":"173","key":"663_CR20","first-page":"2985","volume":"2004","author":"X Chen","year":"1950","unstructured":"Chen X, Doffek K, Sugg SL, Shilyansky J. Phosphatidylserine regulates the maturation of human dendritic cells. J Immunol Baltim Md. 1950;2004(173):2985\u201394.","journal-title":"J Immunol Baltim Md"},{"key":"663_CR21","doi-asserted-by":"crossref","first-page":"29863","DOI":"10.1074\/jbc.M605252200","volume":"281","author":"TA Luster","year":"2006","unstructured":"Luster TA, He J, Huang X, Maiti SN, Schroit AJ, de Groot PG, et al. Plasma protein \u03b2-2-glycoprotein 1 mediates interaction between the anti-tumor monoclonal antibody 3g4 and anionic phospholipids on endothelial cells. J Biol Chem. 2006;281:29863\u201371.","journal-title":"J Biol Chem"},{"key":"663_CR22","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1158\/1078-0432.CCR-04-1645","volume":"11","author":"S Ran","year":"2005","unstructured":"Ran S, He J, Huang X, Soares M, Scothorn D, Thorpe PE. Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res. 2005;11:1551\u201362.","journal-title":"Clin Cancer Res"},{"key":"663_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/ITT.S134834","volume":"7","author":"O Belzile","year":"2018","unstructured":"Belzile O, Huang X, Gong J, Carlson J, Schroit AJ, Brekken RA, et al. Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer. ImmunoTargets Ther. 2018;7:1\u201314.","journal-title":"ImmunoTargets Ther."},{"key":"663_CR24","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1245\/s10434-013-3413-8","volume":"21","author":"AC Yopp","year":"2014","unstructured":"Yopp AC, Mansour JC, Beg MS, Arenas J, Trimmer C, Reddick M, et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol. 2014;21:1287\u201395.","journal-title":"Ann Surg Oncol"},{"key":"663_CR25","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2015. \n                    https:\/\/www.R-project.org\/\n                    \n                  ."},{"key":"663_CR26","first-page":"7","volume":"6","author":"M Plummer","year":"2006","unstructured":"Plummer M, Best N, Cowles K, Vines K. CODA: convergence diagnosis and output analysis for MCMC. R News. 2006;6:7\u201311.","journal-title":"R News"},{"key":"663_CR27","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1002\/sim.3680","volume":"28","author":"D Lunn","year":"2009","unstructured":"Lunn D, Spiegelhalter D, Thomas A, Best N. The BUGS project: evolution, critique and future directions. Stat Med. 2009;28:3049\u201367.","journal-title":"Stat Med"},{"key":"663_CR28","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","volume":"31","author":"A-L Cheng","year":"2013","unstructured":"Cheng A-L, Kang Y-K, Lin D-Y, Park J-W, Kudo M, Qin S, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31:4067\u201375.","journal-title":"J Clin Oncol"},{"key":"663_CR29","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","volume":"33","author":"C Cainap","year":"2015","unstructured":"Cainap C, Qin S, Huang W-T, Chung IJ, Pan H, Cheng Y, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015;33:172\u20139.","journal-title":"J Clin Oncol"},{"key":"663_CR30","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","volume":"31","author":"PJ Johnson","year":"2013","unstructured":"Johnson PJ, Qin S, Park J-W, Poon RTP, Raoul J-L, Philip PA, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31:3517\u201324.","journal-title":"J Clin Oncol"},{"key":"663_CR31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00432-013-1528-8","volume":"140","author":"L Gu","year":"2014","unstructured":"Gu L, Liu H, Fan L, Lv Y, Cui Z, Luo Y, et al. Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2014;140:199\u2013210.","journal-title":"J Cancer Res Clin Oncol"},{"key":"663_CR32","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","volume":"57","author":"J Bruix","year":"2012","unstructured":"Bruix J, Raoul J-L, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57:821\u20139.","journal-title":"J Hepatol"},{"key":"663_CR33","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00432-018-2610-z","volume":"144","author":"O Abdel-Rahman","year":"2018","unstructured":"Abdel-Rahman O. Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study. J Cancer Res Clin Oncol. 2018;144:901\u20138.","journal-title":"J Cancer Res Clin Oncol"},{"key":"663_CR34","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2017.06.026","volume":"67","author":"J Bruix","year":"2017","unstructured":"Bruix J, Cheng A-L, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol. 2017;67:999\u20131008.","journal-title":"J Hepatol"},{"key":"663_CR35","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S1470-2045(09)70171-8","volume":"10","author":"S Faivre","year":"2009","unstructured":"Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 2009;10:794\u2013800.","journal-title":"Lancet Oncol."},{"key":"663_CR36","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet Lond Engl. 2018;391:1163\u201373.","journal-title":"Lancet Lond Engl."},{"key":"663_CR37","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1158\/1078-0432.CCR-08-1141","volume":"15","author":"NS Azad","year":"2009","unstructured":"Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res. 2009;15:1411\u20136.","journal-title":"Clin Cancer Res"},{"key":"663_CR38","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","volume":"66","author":"BE Houk","year":"2010","unstructured":"Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010;66:357\u201371.","journal-title":"Cancer Chemother Pharmacol"},{"key":"663_CR39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40262-013-0108-z","volume":"53","author":"M Fukudo","year":"2014","unstructured":"Fukudo M, Ito T, Mizuno T, Shinsako K, Hatano E, Uemoto S, et al. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. Clin Pharmacokinet. 2014;53:185\u201396.","journal-title":"Clin Pharmacokinet"},{"key":"663_CR40","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","volume":"30","author":"TJ Lynch","year":"2012","unstructured":"Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30:2046\u201354.","journal-title":"J Clin Oncol"},{"key":"663_CR41","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455\u201365.","journal-title":"N Engl J Med"},{"key":"663_CR42","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354.","journal-title":"N Engl J Med"},{"key":"663_CR43","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","volume":"16","author":"AX Zhu","year":"2015","unstructured":"Zhu AX, Park JO, Ryoo B-Y, Yen C-J, Poon R, Pastorelli D, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16:859\u201370.","journal-title":"Lancet Oncol."},{"key":"663_CR44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/JHC.S79353","volume":"2","author":"S Lee","year":"2015","unstructured":"Lee S, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, et al. Early \u03b1-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib. J Hepatocell Carcinoma. 2015;2:39\u201347.","journal-title":"J Hepatocell Carcinoma."},{"key":"663_CR45","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/MEG.0b013e32835d913b","volume":"25","author":"T Nakazawa","year":"2013","unstructured":"Nakazawa T, Hidaka H, Takada J, Okuwaki Y, Tanaka Y, Watanabe M, et al. Early increase in \u03b1-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol. 2013;25:683\u20139.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"663_CR46","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1634\/theoncologist.2011-0105","volume":"16","author":"T Yau","year":"2011","unstructured":"Yau T, Yao TJ, Chan P, Wong H, Pang R, Fan ST, et al. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist. 2011;16:1270\u20139.","journal-title":"Oncologist"},{"key":"663_CR47","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet Lond Engl. 2017;389:2492.","journal-title":"Lancet Lond Engl."},{"issue":"Suppl 1","key":"663_CR48","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000481245","volume":"93","author":"M Kudo","year":"2017","unstructured":"Kudo M. Immuno-oncology in hepatocellular carcinoma: 2017 update. Oncology. 2017;93(Suppl 1):147\u201359.","journal-title":"Oncology."},{"key":"663_CR49","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.2017.35.15_suppl.4073","volume":"35","author":"RK Kelley","year":"2017","unstructured":"Kelley RK, Abou-Alfa GK, Bendell JC, Kim T-Y, Borad MJ, Yong W-P, et al. Phase I\/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses. J Clin Oncol. 2017;35:4073.","journal-title":"J Clin Oncol"},{"key":"663_CR50","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13058-016-0708-2","volume":"18","author":"MJ Gray","year":"2016","unstructured":"Gray MJ, Gong J, Hatch MMS, Nguyen V, Hughes CCW, Hutchins JT, et al. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. Breast Cancer Res BCR. 2016;18:50.","journal-title":"Breast Cancer Res BCR."},{"key":"663_CR51","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/2326-6066.CIR-15-0250","volume":"4","author":"BD Freimark","year":"2016","unstructured":"Freimark BD, Gong J, Ye D, Gray MJ, Nguyen V, Yin S, et al. Antibody-mediated phosphatidylserine blockade enhances the antitumor responses to CTLA-4 and PD-1 antibodies in melanoma. Cancer Immunol Res. 2016;4:531\u201340.","journal-title":"Cancer Immunol Res"},{"issue":"51","key":"663_CR52","first-page":"2501","volume":"2015","author":"JG Monzon","year":"1990","unstructured":"Monzon JG, Hay AE, McDonald GT, Pater JL, Meyer RM, Chen E, et al. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome. Eur J Cancer Oxf Engl. 1990;2015(51):2501\u20137.","journal-title":"Eur J Cancer Oxf Engl"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-019-00663-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-019-00663-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-019-00663-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:01:29Z","timestamp":1597708889000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-019-00663-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,19]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["663"],"URL":"https:\/\/doi.org\/10.1007\/s11523-019-00663-3","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,19]]},"assertion":[{"value":"19 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by Peregrine Pharmaceuticals, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AAM, HZ, YA, JD, and ACY have no conflicts of interest that might be relevant to the contents of this manuscript. MSB has served in a consulting\/advisory role for Cegene, Ipsen, Genentech\/Roche, Guardant Health, and Boston Biomedical; on a speaker\u2019s bureau for Ipsen, Genentech\/Roche, and Bristol-Myers Squibb; and has received research funding from Gelgene, Bristol-Myers Squibb, AstraZeneca\/MedImmune, Merk Serono, Agios, Five Prime Therapeutics, MedImuune, Tolero Pharmaceuticals, ArQule, Genetech, Sillajen, and CASI Pharmaceuticals. AGS has served in a consultant\/advisory role for Eisai, Exelixis, Bayer, and BMS and on a speaker\u2019s bureau for Bayer and BMS.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}